The importance of targeting intracrinology in prostate cancer management
Accumulating evidence has shown that intracrinology in prostate cancer (PCa) has a pivotal role in survival of cancer cell. PCa cells are able to produce androgens from different androgen precursors, such as dehydroepiandrosterone, thereby maintaining androgen receptor signaling. Several drugs have been developed that target intracrinology, some of which are now being used as standard treatment for the so-called castrate-resistant prostate cancer (CRPC) patients. Recently, the US FDA approval has changed the indication of drugs targeting intracrinology, e.g., abiraterone and enzalutamide where it evolved from post-chemotherapy CRPC to hormone-naive metastatic PCa cases. This approval raises question whether those drugs can also be used as the first-line treatment in localized stage PCa cases. In addition, development of additional drugs targeting major components of intracrinology is ongoing. Application of these new drugs and administration of combinations of existing drugs will ultimately lead to an increase in the efficacy of such treatments as well as to reduce the toxicity of the therapy and to prevent the risk of resistance.
KeywordsAbiraterone Androgen deprivation therapy Enzalutamide Intracrinology Prostate cancer
Compliance with ethical standards
Conflict of interest
None of the contributing authors have any conflict of interest, including specific financial interests or relationships and affiliations relevant to the subject matter or materials discussed in the manuscript.
- 18.Kluetz PG, Ning YM, Maher VE, Zhang L, Tang S, Ghosh D (2013) Abiraterone acetate in combination with prednisone for the treatment of patients with metastatic castration-resistant prostate cancer: U.S. food and drug administration drug approval summary. Clin Cancer Res 19(24):6650–6656CrossRefGoogle Scholar
- 23.Ryan CJ, Smith MR, Fizazi K, Saad F, Mulders PF, Sternberg CN (2015) Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, doube-blind, placebo-controlled phase 3 study. Lancet Oncol 16(2):152–160CrossRefGoogle Scholar